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Abstract
Background: Pediatric brain tumors are the most common solid tumors in children. Advances in understanding
the hallmarks of cancer biology and novel therapies have led to an increasing number of survivors of childhood
brain tumors (SCBT). However, these survivors are at an increased risk of obesity and cardiometabolic disorders that
affect their quality of life and lifespan. It is important to define effective strategies to treat and prevent obesity in
this population. This systematic review aims to investigate the effectiveness of lifestyle interventions, pharmacotherapy,
and bariatric surgery on treating obesity in SCBT.
Methods: Searches will be conducted in PubMed, MEDLINE, EMBASE, PsycINFO, SPORTDiscus, CINAHL, Cochrane
Database of Systematic Review, Cochrane Central Register of Controlled Trials (CENTRAL), and Database of Abstracts of
Reviews of Effect (DARE). In addition, ClinicalTrials.gov and ProQuest Dissertations and Theses A&I will be searched to
identify relevant gray literature. The reference lists of eligible articles will be searched for additional studies. All
screening, quality assessment, and data abstraction will be done independently by two reviewers. We will perform
meta-analysis if there are sufficient studies.
Discussion: This review will summarize evidence for the effectiveness of interventions used to reduce obesity risk in
SCBT. This has significant implications for SCBT, as it can identify gaps in knowledge and provide insights into the
development of new interventions to manage obesity in survivors, which may improve their outcomes.
Systematic review registration: PROSPERO CRD42015025909
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Introduction
Brain tumors are the most common solid tumors in chil-
dren and constitute up to 20 % of childhood cancers [1].
Significant breakthroughs in understanding the hall-
marks of cancer biology, coupled with advances in diag-
nostic imaging and improved therapies, have enhanced
the survival rates of these children [2, 3].
As the number of survivors of childhood brain tumors
(SCBT) increased, it has become apparent that survivors
remain at risk of premature mortality [4–6] and the de-
velopment of multiple comorbidities [7, 8]. Many SCBT
develop chronic health conditions within years of their
initial diagnosis [9], and one such morbidity is obesity
[10–13]. In one study, obesity was reported in 36.5 % of
SCBT, compared to 29 % in the general population [14,
15]. In the general population, the annual healthcare ex-
penditures of obese individuals are about US$1360
higher than for their non-obese counterparts [16], and
this is likely to be replicated in SCBT.
Addressing obesity in SCBT is crucial, as it increases
the risk of cardiometabolic disorders in a similar fashion
to the general population, and may contribute to prema-
ture mortality [17, 18]. Obesity is an independent risk
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factor for decreased survival in some children with brain
tumors [19]. Understanding the drivers of obesity in
SCBT will allow the development of precision-based
strategies for reducing the risk of obesity and its cardio-
metabolic comorbidities, which in turn may improve the
quality of life and lifespan of SCBT.
Obesity in SCBT is multifactorial and can be related to
altered energy intake [20, 21], reduced mobility and
physical activity [22–25], hypothalamic-pituitary damage
[11], pituitary hormone deficiencies [26], sleep problems
[27], vision problems, imbalance and pain [8, 28], mental
health issues, and medications, e.g., antidepressants [29].
As obese children are likely to become obese adults
[30–34], it is important to develop effective interven-
tions to manage obesity from an early age. The purpose
of this systematic review is to evaluate current evidence
of effectiveness of interventions to manage obesity in
SCBT.
Research question
In survivors of childhood brain tumors, are the current
interventions including lifestyle intervention, pharmaco-
therapy, and bariatric surgery effective in managing
obesity?
Study objectives
1) Measure the effectiveness of lifestyle interventions,
pharmacotherapy, and bariatric surgery in the
treatment of obesity in SCBT
2) Conduct a meta-analysis of primary studies, if
appropriate, to gain a more precise estimate of the
effectiveness of different strategies in managing
obesity
3) Critically appraise existing evidence and identify
gaps in the literature to provide future research
directions
Methods
The protocol for this systematic review is developed and
reported with guidance from the Preferred Reporting
Items for Systematic Review and Meta-Analysis-Protocols
(PRISMA-P) statement (Additional file 1) [35].
Eligibility criteria
This review will include studies involving boys and girls
who are overweight or obese (BMI z-score ≥85th per-
centile) [36], with a diagnosis of brain tumor made
under the age of 18 years. Randomized controlled trials
(RCTs), quasi-RCTs, prospective or retrospective cohort
studies, case-control studies, cross-sectional studies, and
controlled or uncontrolled studies with before-and-after
comparisons will be included [37].
There will be no restriction to the language or timing
of publication. Conference proceedings, congress re-
ports, and editorials will be hand searched for suggested
relevant studies. We will exclude interim analyses, case
reports, and pilot studies.
In studies where SCBT are included in an intervention
with other cancer types, we will extract data for the
brain tumor subgroup. If the data from subgroups are
not published or pooled with data from survivors of
other cancers, we will attempt to contact the authors to
obtain the subgroup data.
The interventions included in the study are
 Lifestyle intervention: any form of modifications in
subjects’ daily life including their dietary patterns,
physical activity, and eating behaviors
 Pharmacotherapy: any administration of medications
 Bariatric surgery: any surgical approach performed
with the intention of treating obesity, including
adjustable gastric banding, sleeve gastrectomy,
biliopancreatic diversion with duodenal switch, and
gastric bypass
Studies that are entered into the databases up to
February 1, 2016, will be screened for eligibility. The




The primary outcome in this review is BMI z-score
change from baseline to the end of the intervention and/
or at follow-up.
Secondary outcomes
Secondary outcomes include changes in waist and hip
circumference, waist-to-hip ratio, waist-to-height ratio,
body fat percentage, and blood pressure as reported. We
will also report changes in diabetes status, insulin resist-
ance, and non-alcoholic fatty liver disease, if available. In
addition, we will document changes in lipid levels in-
cluding high-density lipoprotein, low-density lipoprotein,
cholesterol, and triglycerides, if reported.
We will also abstract any adverse events observed
during the study. Adverse events directly related to life-
style interventions include back and shoulder pain,
musculoskeletal injuries, and others [38, 39]. Adverse
events for the pharmacological agents include insom-
nia, headaches, hypertension, and others [40]. Adverse
outcomes for bariatric surgery include surgical compli-
cations, perioperative outcomes, and mortality as de-
fined previously [41]. Additional adverse events will be
included as reported.
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Search strategy
We will consult a Health Sciences librarian with expertise
in systematic reviews when designing the search strategy.
A proposed search strategy for MEDLINE is described in
Table 1. Searches will be conducted in PubMed, MED-
LINE, EMBASE, PsycINFO, SPORTDiscus, CINAHL,
Cochrane Database of Systematic Review, Cochrane Cen-
tral Register of Controlled Trials (CENTRAL), and
Database of Abstracts of Reviews of Effect (DARE). We
will search ClinicalTrials.gov and ProQuest Disserta-
tions and Theses A&I to identify relevant gray litera-
ture. We will also search the reference lists of articles
deemed eligible for inclusion in the analysis for relevant
studies.
Data management
Two independent reviewers will perform data abstrac-
tion and quality assessment. Disagreement between the
two reviewers will be resolved by discussion, with subse-
quent involvement of a third reviewer to arbitrate
disagreements. Excel spreadsheets will be used to
manage study records during the screening process.
We will use the Grading of Recommendations Assess-
ment, Development and Evaluation Profiler (GRADE-
pro) software to create tables for summary of findings
and quality assessment [42].
Data screening
Duplicates will be removed, followed by screening of ti-
tles and abstracts. Full-text articles that meet the inclu-
sion criteria will be retrieved and screened. Screening at
all steps will be conducted independently by two
reviewers, who will meet after each step to ensure
consistency and to resolve conflicts. In the case of per-
sisting disagreement, a third reviewer will be consulted.
A flow diagram will be included to report the screening
process (Fig. 1) [43, 44].
Data abstraction
Data will be extracted independently by two reviewers,
using a data abstraction form specifically designed for
this systematic review. Details to be collected include
title, authors, publication date, journal name, setting,
country, funding source, study design, study duration,
eligibility criteria, sample size, and methods used for
brain tumor diagnosis including imaging, histology, and
clinical assessment.
Participants’ characteristics include age at diagnosis of
brain tumor and at study enrollment, sex, ethnicity, and
brain tumor location and laterality. Treatment details
include radiotherapy type (fractionated or non-fractionated)
and dose, chemotherapy type, dose and duration, and sur-
gery details (total resection, partial resection, shunting, ven-
triculostomy, others).
Detailed description of the obesity interventions will
be recorded including study design, components, dur-
ation, and adverse events. We will document primary
and secondary outcomes of the studies. Adjustment for
confounders and details of the statistical analyses per-
formed will be extracted as well as study results. We will
attempt to retrieve incomplete data by contacting the
corresponding authors of published work.
Quality assessment
The Risk of Bias Assessment Tool from the Cochrane
Collaboration will be used to assess RCT [45]. This tool
includes six domains: sequence generation, allocation con-
cealment, blinding, incomplete data, selective reporting
outcomes, and other sources of bias. Each RCT will be
rated as having either a high, low, or unclear risk of bias.
The Risk of Bias In Non-randomized Studies—of In-
terventions (ROBINS-I) assessment tool will be used for
non-randomized studies such as cohort studies [46].
This tool includes three domains: pre-intervention, at-
intervention, and post-intervention.
In the pre-intervention domain, bias due to confound-
ing and participant selection are evaluated. Possible con-
founding factors include brain tumor location, type,
treatments, years of survival, age, sex, pubertal stage,
baseline body composition, and presence of comorbidi-
ties such as metabolic syndrome and hormonal
Table 1 Search strategy for MEDLINE (Continued)
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deficiency. Bias due to misclassification of the interven-
tion status is assessed in the at-intervention domain.
The post-intervention domain includes bias due to depar-
tures from the intended interventions, missing data,
methods of outcome measurements, and selective report-
ing outcomes. In particular, co-interventions between life-
style interventions, pharmacotherapy, and bariatric surgery
can contribute to bias during the post-intervention
domain. For example, participants may take antiobe-
sity agents while they are on diet restriction. Each
non-randomized study will be rated as having either a
low, moderate, serious, critical, or unclear risk of
bias.
The quality of uncontrolled studies will be assessed
with a checklist developed by the University of Alberta
Evidence-based Practice Center (UAEPC) [47]. This
checklist evaluates selection bias, incomplete data, and
the methods of outcome assessments. We will tabulate
risk of bias for all included studies and discuss its impact
on the meta-analysis.
The quality of evidence will be assessed using the
Grading quality of evidence and strength of recommen-
dations (GRADE) guidelines [48]. The GRADE guideline
covers risk of bias, inconsistency, indirectness, impreci-
sion, and publication bias. The overall quality of evi-
dence is reported by each outcome measure as high,
moderate, low, or very low.
Data analysis
Detailed characteristics of the included studies will be
provided, in addition to a meta-analysis if applicable. We
will analyze each intervention separately, and outcomes
will be analyzed separately based on study designs. We
will perform a meta-analysis if two or more studies are
identified per intervention.
Dichotomous outcomes will be reported as odds ratio,
while continuous outcomes will be reported as standard-
ized mean differences and 95 % confidence intervals.
Expecting high levels of heterogeneity, our primary ap-
proach will emphasize the random effects estimate if
more than ten studies can be identified [49]. Otherwise,
both random effect and fixed effect models will be
presented.
Inconsistency index (I2) and P values will be used to
quantify heterogeneity. The interpretation of the I2 will
be based on the threshold set by the Cochrane
Records identified through 
database searches
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Additional records identified 
from other sources
Grey literature (n=  )
Reference lists of relevant 
studies (n =   )
Total records with duplicates
(n =   )
Titles screened
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(n =   )
Full-text articles 
screened (n =   )
Full-text articles
excluded, with reasons
(n =   )
Studies included in 
qualitative synthesis
(n =   )
Studies included in 
quantitative synthesis 
(meta-analysis)
(n =   )
Abstracts screened
(n =   )
Titles excluded, 
with reasons
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Abstracts excluded, 
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Exclusion of conference 
proceedings, editorials, 
congress reports, etc.
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Fig. 1 Flow diagram of the article screening process
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Collaboration [50]. If appropriate, a stratified analysis by
sex will be pursued to identify a source of heterogeneity,
as female SCBT are more at risk of developing obesity
than males [8, 10].
If sufficient studies are identified for an outcome
(≥10), we will perform sensitivity analysis by excluding
outlier, small-sized, or highly biased studies to determine
the impact of these studies on the meta-analysis result.
To investigate publication bias, we will create a contour-
enhanced funnel plot and use Egger’s test and visual in-
spection to determine plot asymmetry, if there are ten or
more studies for an outcome [51].
All meta-analyses will be conducted using Review
Manager software version 5.3 (RevMan 5.3) [52] while
Comprehensive Meta-Analysis software version 3 (CMA
3.0) will be used for Egger’s test [53]. When meta-
analysis is not appropriate, a table for summary of find-
ings will be created using GRADEpro software and a
narrative summary will be reported. The results of this
systematic review will be presented according to the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [43, 44]. When
amendments of the protocol are needed, we will docu-
ment the date and the rationale for these changes.
Discussion
As the number of SCBT increased over time, it has be-
come apparent that the burden of surviving a brain
tumor is significant [4, 6, 12, 13]. Obesity is a critical co-
morbidity to address in survivors, as it drives the risk of
cardiovascular diseases, type 2 diabetes, metabolic syn-
drome, and hypertension [7, 8, 17–19]. This reduces the
quality of life and lifespan of the survivors and increases
healthcare system utilization.
In order to improve health outcomes in SCBT, it is im-
portant to develop evidence-based interventions to treat
and prevent obesity and its cardiometabolic comorbidities.
The findings from this systematic review will have im-
portant implications for SCBT, as it will provide insights
into the current best form of obesity intervention for
these patients. The review will also define gaps in know-
ledge and help improve the quality of life and lifespan of
SCBT by guiding the design of new interventions to tar-
get obesity and its cardiometabolic comorbidities.
Additional file
Additional file 1: PRISMA-P checklist. This checklist includes recommended
items to address in a systematic reviews protocol and their location in this
protocol. (DOCX 40 kb)
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